Related Experiment Video
Updated: Jun 12, 2025

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
Published on: December 16, 2021
Immune checkpoint inhibitor-induced diarrhea and colitis: an overview
Marianne Zoghbi1, Kathryn J Burk2, Elio Haroun3
1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mzoghbi@mdanderson.org.
Immune checkpoint inhibitors (ICIs) can cause gastrointestinal issues like diarrhea and colitis. Understanding risk factors and management is key for balancing cancer treatment efficacy and patient safety.
Area of Science:
- Oncology
- Immunology
- Gastroenterology
Background:
- Immune checkpoint inhibitors (ICIs) targeting CTLA-4 and PD-1/PD-L1 have improved cancer survival.
- Gastrointestinal immune-related adverse events (irAEs), particularly immune-mediated diarrhea and colitis (IMDC), are common ICI complications.
Purpose of the Study:
- To enhance understanding of gastrointestinal adverse events associated with ICIs, focusing on IMDC.
- To review risk factors, incidence, clinical presentation, and management of IMDC.
Main Methods:
- Literature review of immune checkpoint inhibitors and their gastrointestinal side effects.
- Analysis of risk factors, clinical manifestations, and current/investigational treatments for IMDC.
Main Results:
- Risk factors for IMDC include gut microbiota, autoimmune disorders, and cancer type.
- IMDC symptoms include diarrhea, abdominal pain, fever; rapid treatment is crucial to prevent severe complications.
Conclusions:
- Optimal patient care necessitates balancing ICI efficacy with toxicity management.
- Further research into novel treatments like microbiota transplantation is ongoing.
More Related Videos
08:37Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
Published on: April 21, 2015
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...